Jefferies analyst Biren Amin reiterated a Hold rating on NantKwest (NK) on November 12 and set a price target of $3.50. The company’s shares closed yesterday at $2.20, close to its 52-week low of $2.01.
According to TipRanks.com, Amin is a 5-star analyst with an average return of 12.6% and a 50.5% success rate. Amin covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics Inc, Urovant Sciences Ltd, and Fate Therapeutics.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for NantKwest with a $3.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.47 and a one-year low of $2.01. Currently, NantKwest has an average volume of 466.9K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N.
